Novo Nordisk has slashed the cash price of its blockbuster weight-loss drug Wegovy to $349 per month, accelerating a pricing deal it had originally planned to implement in January under a previously announced agreement with the Trump administration. The move marks a major shift in the escalating competition among companies racing to dominate the fast-growing obesity-drug market.

The Danish drugmaker also lowered the price for most doses of its diabetes drug Ozempic to the same level, with the exception of the highest 2 mg dose, which remains at $499.

The announcement comes during a pivotal moment for the company, which is undertaking deep restructuring and facing increasing pressure from rival Eli Lilly and from the proliferation of cheaper semaglutide copies available through pharmacies and telehealth platforms.

What Novo Nordisk announced and why it matters

Novo Nordisk said it has begun selling Wegovy for $349 per month to cash-paying patients, significantly undercutting its previous price of $499. The earlier-than-planned reduction is intended to streamline access to FDA-approved semaglutide products amid a flood of lower-priced alternatives entering the U.S. market.

The new pricing matches the div President Donald Trump announced earlier this month when unveiling a deal with Novo and Eli Lilly to reduce out-of-pocket costs for obesity and diabetes medicines beginning in January.

By moving ahead of schedule, Novo Nordisk is signaling a strategic shift aimed at shoring up market share as competitors expand.

The expanded access plan and introductory $199 offer

As part of its broader affordability strategy, Novo Nordisk rolled out a discounted introductory offer of $199 per month for first-time cash-paying users of the two lowest doses of Wegovy and Ozempic.
The deal is valid for two months for patients who begin treatment anytime between now and March 31, 2026.

Patients can access these offers through:

• The Ozempic and Wegovy official websites
• Novo Nordisk’s consumer portal NovoCare
• Partner platforms including GoodRx, WeightWatchers, and Costco

The initiative aims to make authentic semaglutide more accessible to individuals who are increasingly turning to compounded or non-FDA-approved versions due to cost and supply issues.

Competing pressure from Eli Lilly and rising demand for obesity drugs

Novo’s decision comes shortly after Eli Lilly announced that its lowest dose of Zepbound, a direct competitor to Wegovy, will be priced at $299 per month for cash-paying customers starting in January. Higher doses will cost $449 per month under Lilly’s new pricing plan.

Lilly has gained momentum over the past year by moving quickly to broaden access and capitalize on skyrocketing interest in medical weight-loss options. Its pricing strategy has intensified pressure on Novo Nordisk to respond.

The obesity-drug market is expected to grow into a multi-billion-dollar sector globally over the next decade, making affordability and access critical in determining long-term market leaders.

GoodRx enters the space with new telehealth service

In a sign of how competitive the market has become, GoodRx announced Monday it will launch a weight-loss telehealth service offering Wegovy and Ozempic access for subscribers.
The service will cost:

• $39 per month for users who sign up before February 1, 2026
• $119 per month thereafter

This move positions GoodRx as a major telehealth provider for weight-loss prescriptions, adding further pricing pressure to manufacturers and other telemedicine platforms.

Internal challenges at Novo Nordisk and a strategic shift under new leadership

Novo Nordisk has been undergoing substantial internal restructuring. After appointing Mike Doustdar as its new CEO in August, the company announced 9,000 layoffs globally and initiated a sweeping reset of its business strategy.

Doustdar’s leadership marks a decisive turn for a company that has struggled to keep pace with Lilly in both production scale and market adaptation. Accelerating price reductions for Wegovy and Ozempic aligns with Novo’s efforts to regain momentum in the U.S. market.

How the government deal shapes future pricing for obesity treatments

Under the agreement reached with the Trump administration:

• Starter doses of upcoming weight-loss pills from both Novo and Lilly—if approved—will be priced at $149 per month for Medicare, Medicaid, and cash-paying consumers via the government’s new TrumpRx platform
• Injectable obesity drugs from both companies will be sold to Medicare and Medicaid for a net price of $245 per month

The new pricing for Wegovy and Ozempic aligns with these goals and positions Novo Nordisk to better meet the expectations set by the White House for broader access and affordability.

What this means for consumers and the obesity-drug landscape

For cash-paying patients, the immediate impact is significant. With prices dropping from $499 to $349—and in some cases as low as $199—Wegovy and Ozempic become more attainable for millions of Americans without insurance coverage for weight-loss medications.

The market is also poised for rapid expansion as telehealth platforms like GoodRx enter the field with lower-cost services, and as government-backed price ceilings influence future product launches.

Competition is intensifying, innovation is accelerating, and pricing strategies are becoming central to the next chapter of the obesity-drug boom.